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A B S T R A C T
We present a 48-year-old female patient who developed rosacea-like demodicosis af-
ter seven days of topical application of 1% pimecrolimus cream. The inflammatory 
infiltrate in the lesions was mainly composed of T-cells with a CD4+/CD8+ ratio 
= 0.33; B-cells (CD20+) and NK-cells (CD56+) were not detected. Large numbers 
of (CD68+) histiocytes were demonstrated, whereas the number of Langerhans cells 
(CD1a+) revealed no significant alteration. The reduced CD4+:CD8+ ratio may have 
led to a modification of follicular microenvironment favouring the excessive prolifera-
tion of Demodex mites, who triggered a presently unknown sequence of events leading 
to the development of pimecrolimus-induced rosacea-like demodicosis.
I N T R O D U C T I O N
Demodex folliculorum and Demodex brevis are obligatory ectoparasites in the fol-
licular infundibulum and in the sebaceous ducts and meibomian glands, respectively. 
Demodex mites do not cause clinical manifestations in most infected individuals, 
unless local or systemic immune function of the host is impaired, follicular infesta-
tion is heavy and the mites penetrate into the dermis1-3. Demodicosis is a term used 
to describe cutaneous disorders caused by Demodex mites including papulopustular 
rosacea, pustular folliculitis, perioral dermatitis, rosacea-like demodicosis, pityriasis 
folliculorum, demodicosis gravis, blepharitis and demodex granuloma4.
We describe herein a patient with seborrheic dermatitis who developed a rosacea-like 
demodicosis with abundant Demodex mites subsequent to a 7-day topical application 
of 1% pimecrolimus cream.
C A S E  R E P O R T
A 48-year-old HIV negative female Caucasian patient with a 5-year history of facial 
seborrheic dermatitis presented with cutaneous lesions (accompanied by a burning 
sensation) that had suddenly developed after seven days of effective and well-toler-
ated topical application of 1% pimecrolimus cream (Elidel, Novartis Hellas S.A., 
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Athens, Greece) prescribed by her dermatologist. She had 
previously been treated with topical antimycotics (ketocona-
zole cream 2%; Fungoral, Janssen-Cilag, Athens, Greece) or 
steroids (dexamethasone 0.1 % cream, Thilodexine, Farmex 
S.A., Athens, Greece) with varying success; however, she had 
received no systemic or topical medications for treatment of 
the last exacerbation of her seborrheic dermatitis prior to the 
initiation of pimecrolimus. During pimecrolimus treatment 
she had not been exposed to sunlight, artificial UV-light 
or infrared radiation and had received no other topical or 
systemic medication. The patient denied any previous history 
of alcohol ingestion, rosacea, acne or perioral dermatitis. 
Physical examination revealed erythematous and edematous 
papules and plaques on the nasolabial folds, cheeks, perioral 
and periorbital areas (Fig. 1).
Routine laboratory investigations including flow cytometry 
analysis of peripheral lymphocyte subpopulations revealed 
no abnormalities. Potassium hydroxide examination of skin 
scrapings showed numerous Demodex mites. Histopathologi-
cal examination of a lesional skin biopsy revealed a dermal 
perivascular and diffuse predominantly lymphocytic infiltrate 
mixed with histiocytes. Lymphocytes, isolated and in small 
clusters, had penetrated into the slightly parakeratotic and 
spongiotic epidermis (Fig. 2A), whereas 3-5 Demodex mites 
were seen in hair follicles (Figs. 2B & 2C), suggesting a ro-
sacea-like demodicosis. Immunohistochemical investigation 
performed for the first time in this study revealed that the 
lymphocytic infiltrate was mainly composed of T-cells (CD3+ 
and CD5+) with a predominance of CD8+ relative to CD4+ 
lymphocytes and a CD4+/CD8+ ratio = 0.33 (Figs. 2D & 2E); 
B-cells (CD20+) and NK-cells (CD56+) were not detected. 
Large numbers of (CD68+) histiocytes were demonstrated, 
whereas the number of Langerhans cells (CD1a+) revealed 
no significant alteration. After 4 weeks of treatment with 50 
mg oral minocycline hydrochloride (Minocin caps 50 mg, 
Teofarma, Athens, Greece) twice daily, the patient revealed 
a complete resolution of her facial lesions.
D I S C U S S I O N
Topical pimecrolimus, a representative of macrolactam 
immunomodulators, is an effective and safe second-line mo-
dality for the short-term and intermittent management of 
non-immunocompromised patients with atopic and seborrheic 
dermatitis and other dermatoses unresponsive to, or intoler-
ant of other treatments5-7. Its side effects include transient 
local skin reactions (burning/tingling, erythema, pruritus), 
increased incidence of mostly viral cutaneous infections and 
lymphadenopathy5. The patient presented herein had received 
no systemic or topical medications for treatment of the last 
exacerbation of her seborrheic dermatitis prior to the initia-
tion of pimecrolimus. Thus, in view of the morphology of the 
cutaneous manifestations, the identification of numerous 
Demodex mites in skin scrapings and in the hair follicles and 
FIGURE 1. Clinical aspect of pimecrolimus-induced rosacea-
like demodicosis.
FIGURE 2. A. Histopathological aspect of rosacea-like demodi-
cosis, showing Demodex mites within hair follicles and dermal 
lymphocytic infiltrate (hematoxylinosin; original magnification 
x 200); B. & C. Intrafollicular mites at higher magnification 
(hematoxylin-eosin; original magnification x 400); Immunos-
taining of dermal inflammatory infiltrate for CD4 (D; original 
magnification x 200) and CD8 (E; original magnification x 200), 
clearly showing the predominance of CD8+ cells.
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of the temporal relationship between the occurrence of the 
skin lesions and the topical application of this compound, the 
diagnosis of pimecrolimus-induced rosacea-like demodicosis 
was established. To our knowledge, this is the fourth report 
of this disorder (Table 1) in patients with seborrheic or atopic 
dermatitis8-10. However, the potential to cause this rare compli-
cation is also shared by tacrolimus and seems to be a common 
property of topical calcineurin inhibitors11.
In the lesional skin of patients with either atopic or sebor-
rheic dermatitis there is a numerical increase of Langerhans 
cells, as compared to healthy controls12,13. Furthermore, in 
contrast to the inflammatory infiltrate in the lesions of atopic 
and seborrheic dermatitis, in which T-lymphocytes are mostly 
of helper cell phenotype (CD4+)12,13, in the present case CD8+ 
cells predominated over CD4+ cells, although CD4+:CD8+ 
ratio in peripheral blood of the patient was within normal 
limits (2.17). It seems, therefore, reasonable to suggest that 
this distinct immunohistochemical profile may be due to the 
biological action of topical pimecrolimus. Indeed, it is well 
known that the latter mainly acts through inhibition of the 
calcineurin-dependent signal transduction pathway, which is 
required for activation of CD4+ T-lymphocytes14. Thus, the 
reduced CD4+:CD8+ ratio found in the lesional skin of our 
patient may be interpreted in terms of a pimecrolimus-induced 
downregulation of IL-2 synthesis and reduction in the numbers 
of CD4+ lymphocytes. The immunological alterations found in 
the present study support the hypothesis previously put forth 
by other groups8,10 according to which a pimecrolimus-induced 
local immunosuppressive effect may have led to a modifica-
tion of follicular microenvironment favouring the excessive 
proliferation of Demodex mites, who triggered a presently 
unknown sequence of events leading to the development of 
pimecrolimus-induced rosacea-like demodicosis. Further 
studies are now warranted to define the incidence and the 
predisposing factors of this disorder and the role played by 
CD8+ cells in its pathogenetic mechanisms.
TABLE 1. Reported cases of rosacea-like demodicosis after topical application of 1% pimecrolimus cream
No. Sex/age (years) Previous disease Onset time Treatment Reference
1 Female/43 AD 3 days Doxycycline Lübbe et al (2003)
2 Male/36 SD 4 days Minocycline Gorman & White (2005)
3 Male/43 SD 7 days Minocycline Yoon et al (2007)
4 Female/48 SD 7 days Minocycline Present case
AD = atopic dermatitis; SD = seborrheic dermatitis
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